Transaminase Changes in Korean Rheumatoid Arthritis Patients with Chronic Hepatitis C after Biologic Therapy.
10.4078/jrd.2018.25.2.108
- Author:
Hyun Mi KWON
1
;
Kichul SHIN
;
Jin Young MOON
;
Shin Seok LEE
;
Won Tae CHUNG
;
Jisoo LEE
;
Sang Heon LEE
;
Seong Wook KANG
;
Chang Hee SUH
;
Seung Jae HONG
;
Ran SONG
;
Jung Yoon CHOE
;
Yeong Wook SONG
Author Information
1. Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. ysong@snu.ac.kr
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Hepatitis C;
Rheumatoid arthritis;
Biological therapy;
Antirheumatic agents
- MeSH:
Abatacept;
Adalimumab;
Antirheumatic Agents;
Arthritis, Rheumatoid*;
Biological Factors;
Biological Therapy*;
Classification;
Etanercept;
Hepacivirus;
Hepatitis C;
Hepatitis C, Chronic*;
Hepatitis, Chronic*;
Hospitals, University;
Humans;
Infliximab;
Korea;
Liver;
Retrospective Studies;
Rheumatic Diseases;
Rheumatology;
RNA, Viral;
Viral Load
- From:Journal of Rheumatic Diseases
2018;25(2):108-115
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: Coexisting chronic hepatitis C can be problematic when treating rheumatoid arthritis (RA). This study examined the changes in the transaminase and viral load in hepatitis C virus (HCV)-infected RA patients after initiating biologic agents. METHODS: A multicenter retrospective study was conducted at 12 University Hospitals in Korea between November 2014 and November 2015, and 78 RA patients, who met the 2010 American College of Rheumatology and European League Against Rheumatism classification criteria for RA and were concomitantly infected with HCV, were identified. The baseline and longitudinal clinical data, changes in liver function, and viral RNA titers were evaluated. RESULTS: Seventeen (21.8%) patients were treated with biologic agents, including etanercept (n=8), adalimumab (n=8), infliximab (n=2), tocilizumab (n=2), abatacept (n=1), and golimumab (n=1) (median 1.5 patient-years). Four patients experienced marked increases in transaminase during treatment with adalimumab (n=2) and tocilizumab (n=2). Two patients (one using adalimumab, the other using tocilizumab) were treated with anti-viral agents and showed dramatic improvement in both the viral RNA and transaminase. One patient discontinued adalimumab due to the repeated elevated transaminase levels along with a twofold increase in the viral RNA titer, and the transaminase level subsequently normalized. No case of overt viral reactivation was identified. CONCLUSION: The data support that changes in transaminase and/or viral load associated with biologic agents in HCV-infected RA patients are possible. Therefore, the liver function and viral RNA titer should be followed regularly during biologic therapy.
